Intrinsiq Materials Leads 1.3 Million Euro Program to Develop Copper Inks for Medical Device Applications

Intrinsiq Materials is leading a consortium to develop its novel nanoparticle copper ink technology for use in medical devices under the UK government funded PROCID program.

The PROCID programme will run to the end of 2013 and is designed to prove the cost effective use of printed copper in low cost antibody-based biosensors for disease detection, initially targeting the STDs chlamydia and gonorrhea.

The consortium consists of distinguished specialist partners Leeds University, ELISHA Systems Ltd., The Ryedale Group, The Needham Group, Amies Innovations and P1 Technology, with Intrinsiq Materials leading the program and providing their novel copper ink technology.

“Several key potential end-users are assessing our inks in a range of applications, including security, displays and PV,” said Ian Clark, sales and marketing director.”The potential in medical device applications is an exciting development which will be accelerated by the PROCID program.”